Phase 2 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with multiple sclerosis (MS) using 2024 diagnostic criteria, and whose condition has been stable on MS treatment for at least 12 months, with no relapses and no new spots found on a brain MRI scan
- People aged between 18 and 60 years old
- People with a body mass index (BMI) of 27.0 or higher (this means carrying some excess weight relative to height)
Who may not be able to join:
- People who have used a GLP-1 or GIP/GLP-1 weight-loss or diabetes medication in the past year, or who have a known allergy or sensitivity to this type of medication
- People who have been diagnosed with Barrett's oesophagus, gastroesophageal reflux disease (persistent acid reflux), pancreatitis (past or present), or a condition where the stomach empties too slowly (gastroparesis)
- People who have a personal or family history of a specific type of thyroid cancer (medullary thyroid carcinoma) or a genetic condition called multiple endocrine neoplasia syndrome type 2
- People with significant kidney disease, type 1 diabetes, a diabetes-related eye condition (diabetic retinopathy), or who currently use insulin, certain diabetes tablets (including sulphonylureas, meglitinides, or DPP-4 inhibitors), or the blood-thinning medication warfarin
- People with current or active alcohol misuse or use of illicit substances
- People whose neurologist or the study medical team have concerns about their suitability for the trial
- People who are currently pregnant, breastfeeding, or planning a pregnancy in the next two years
- People who could become pregnant and who are not willing or able to use an agreed reliable form of contraception for the duration of the trial — the trial requires either one highly effective method (such as a hormonal implant, IUD, or copper IUD) or two methods used together; the trial site can provide full details of what is accepted (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ellen M Mowry, MD, MCR, Johns Hopkins University
Phone: 667-306-8153
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in normalized (for head size) brain parenchymal volume (nBPV)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.